Vanda Pharmaceuticals Stock Earnings Reports

Vanda Pharmaceuticals reported Q1 2026 results with total net product sales of $51.7M (up 3% vs. Q1 2025). Key commercial drivers were a 26% YoY increase in Fanapt sales ($29.6M) with TRx +32% and NBRx +76% YoY, and the U.S. launch of NEREUS via a direct-to-consumer platform (nereus.us). The FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia; BYSANTI has data exclusivity through Feb 20, 2031 and patents to 2044. Vanda raised 2026 revenue guidance to $240M–$290M (including $10M–$30M expected from NEREUS). Late-stage pipeline milestones expected in 2026–early 2027 include: Phase III BYSANTI adjunctive MDD results (expected Q1 2027), Phase III tradipitant (NEREUS/HETLIOZ tradipitant) results for GLP-1–induced nausea/vomiting (by end of 2026), Phase III VQW-765 for social anxiety (by end of 2026), and a PDUFA date of Dec 12, 2026 for imsidolimab in generalized pustular psoriasis (with pivotal results published in NEJM Evidence). Financially, operating expenses rose (Q1 OpEx $101.9M vs. $91.1M prior year) and Q1 net loss widened to $48.6M. Cash as of March 31, 2026 was $202.3M, down $61.5M vs. Dec 31, 2025 (partly due to a $10M milestone to Eli Lilly, seasonal comp, and higher manufacturing payments); management said 2026 cash burn will likely exceed 2025. Company highlighted continued commercial investments (expanded Fanapt sales force ~300 reps) and a dual-access strategy for NEREUS (cash-pay DTC at a discounted price plus traditional channels over time). Management emphasized that NEREUS guidance ($10M–$30M) is model-based given early launch, and BYSANTI revenue is expected to be driven independently (not simply embedded in Fanapt guidance). Risks noted include ongoing generic competition for HETLIOZ and typical beginning-of-year insurance/deductible impacts on Q1 sales.